CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DALKR1275QPredictiveSupportsResistanceNeuroblastomaALK Inhibitor TAE684George et al., 2008
BDNMT3AR882PrognosticDoes Not SupportAcute Myeloid LeukemiaGaidzik et al., 2013
BDNMT3AR882PrognosticDoes Not SupportPoor OutcomeAcute Myeloid LeukemiaGaidzik et al., 2013
BKITExon 11 MutationPrognosticDoes Not SupportGastrointestinal Stromal TumorWardelmann et al., 2006
BNRASMutationPrognosticDoes Not SupportAcute Myeloid LeukemiaBowen et al., 2005
BNRASG12PrognosticDoes Not SupportAcute Myeloid LeukemiaBacher et al., 2006
BKITExon 11 MutationPredictiveSupportsSensitivity/ResponseMelanomaImatinibHodi et al., 2013
BDNMT3AR882PrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaGaidzik et al., 2013
BDNMT3AR882PrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaGaidzik et al., 2013
BKITExon 14 MutationPrognosticSupportsPoor OutcomeGastrointestinal Stromal TumorWardelmann et al., 2006
BNRASMutationPrognosticSupportsPoor OutcomeMelanomaJakob et al., 2012
BRETMutationPrognosticSupportsPoor OutcomeMedullary Thyroid CarcinomaElisei et al., 2008
DRETC634WPredictiveSupportsResistanceMedullary Thyroid CarcinomaMotesanibCoxon et al., 2012
DRETM918TPredictiveSupportsResistanceMedullary Thyroid CarcinomaMotesanibCoxon et al., 2012
DRETM918TPredictiveSupportsSensitivity/ResponseMedullary Thyroid CarcinomaJAK2 Inhibitor AZD1480Couto et al., 2012
BBRAFV600EDiagnosticSupportsPositiveThyroid CancerHowell et al., 2011
BPIK3CAE542KPredictiveDoes Not SupportResistanceColorectal CancerRegorafenib AnhydrousTabernero et al., 2015
DBRAFV600EPredictiveDoes Not SupportResistanceMelanomaMirdametinib,TrametinibNissan et al., 2014
BBRAFV600PredictiveSupportsResistanceColorectal CancerPanitumumabPeeters et al., 2013
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerPanitumumab,SorafenibDi Nicolantonio et al., 2008
DBRAFV600E AND NF1 LossPredictiveSupportsResistanceMelanomaVemurafenibNissan et al., 2014
BBRAFV600PredictiveSupportsSensitivity/ResponseMelanomaTrametinib,DabrafenibFlaherty et al., 2012
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerPLX4720,Pictilisib BismesylateRad et al., 2013
DBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaNutlin-3,PLX4720Ji et al., 2013
DBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerCapecitabine,Bevacizumab,VemurafenibYang et al., 2012
BBRAFV600EPrognosticSupportsPoor OutcomeMelanomaNagore et al., 2014
BBRAFV600EPrognosticSupportsPoor OutcomePapillary Thyroid CarcinomaHowell et al., 2011
BBRAFV600EPrognosticSupportsPoor OutcomePapillary Thyroid CarcinomaHe et al., 2014
BBRAFV600EPrognosticSupportsPoor OutcomePapillary Thyroid CarcinomaHowell et al., 2011
BNPM1MUTATIONDiagnosticSupportsPositiveAcute Myeloid Leukemia With Mutated NPM1Thiede et al., 2006
BDNMT3AR882DiagnosticSupportsNegativeAcute Myeloid LeukemiaGaidzik et al., 2013
BDNMT3AR882DiagnosticSupportsPositiveAcute Myeloid LeukemiaGaidzik et al., 2013
BDNMT3AR882DiagnosticSupportsPositiveAcute Myeloid LeukemiaGaidzik et al., 2013
BNPM1EXON 11 MUTATIONDiagnosticSupportsPositiveAcute Myeloid LeukemiaThiede et al., 2006
BNPM1EXON 11 MUTATIONDiagnosticSupportsPositiveAcute Myeloid LeukemiaSchlenk et al., 2009
BCEBPAMutationPredictiveDoes Not SupportSensitivity/ResponseAcute Myeloid LeukemiaTretinoinBurnett et al., 2010
BPIK3CAExon 10 MutationPredictiveDoes Not SupportResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
BNRASQ61PredictiveDoes Not SupportResistanceColorectal CancerCetuximabDe Roock et al., 2010
DALKF1174LPredictiveSupportsResistanceNeuroblastomaCrizotinibBresler et al., 2011
BBRAFV600EPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
BFLT3ITDPredictiveSupportsResistanceAcute Myeloid LeukemiaTretinoinBurnett et al., 2010
BFLT3ITDPrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaGale et al., 2008
DFLT3ITDPredictiveSupportsResistanceAcute Myeloid LeukemiaDaunorubicinBagrintseva et al., 2005
DFLT3ITDPredictiveSupportsResistanceAcute Myeloid LeukemiaSU5614Bagrintseva et al., 2005
BKRASG12/G13PredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
DKRASG12/G13PredictiveSupportsResistanceColorectal CancerCetuximabLièvre et al., 2008
BNPM1EXON 11 MUTATIONPredictiveDoes Not SupportSensitivity/ResponseAcute Myeloid LeukemiaTretinoinBurnett et al., 2010
BPIK3CAExon 21 MutationPredictiveSupportsResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
BWT1Exon 7 MutationPredictiveSupportsResistanceAcute Myeloid LeukemiaDaunorubicin,CytarabineVirappane et al., 2008
DEML4::ALKFusion AND ALK L1196MPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAlectinibSakamoto et al., 2011
Page 26 of 96
PreviousNext